Rotavirus Vaccine, Live, Oral, Pentavalent + Comparator: placebo + Comparator: Infanrix(tm) Hexa

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Rotavirus Disease

Conditions

Rotavirus Disease

Trial Timeline

Feb 1, 2006 → Nov 1, 2006

About Rotavirus Vaccine, Live, Oral, Pentavalent + Comparator: placebo + Comparator: Infanrix(tm) Hexa

Rotavirus Vaccine, Live, Oral, Pentavalent + Comparator: placebo + Comparator: Infanrix(tm) Hexa is a phase 3 stage product being developed by Merck for Rotavirus Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT00258154. Target conditions include Rotavirus Disease.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT00258154Phase 3Completed